Company news
Bristol-Myers Squibb and KAI Pharmaceuticals, a privately held biotechnology company, have announced an exclusive agreement for the global development and commercialization of KAI-9803.
<< Return to
Company news
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.